Research graph
References from Anticancer Peptides: Design Principles, Translational Bottlenecks, and Emerging Opportunities. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Trends in peptide drug discovery
10.1038/s41573-020-00135-8 · 2021 · External reference
Therapeutic peptides: Historical perspectives, current development trends, and future directions
10.1016/j.bmc.2017.06.052 · 2018 · External reference
Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification
10.1098/rsob.200004 · 2020 · External reference
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application
10.3892/ijo.2020.5099 · 2020 · External reference
Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications
10.18632/oncotarget.16743 · 2017 · External reference
Cytotoxic and antitumor peptides as novel chemotherapeutics
10.1039/d0np00019a · 2021 · External reference
Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide
10.1021/acs.jmedchem.5b02025 · 2016 · External reference
Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors
10.1158/1078-0432.ccr-20-3435 · 2021 · External reference
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix
10.1126/science.1099191 · 2004 · External reference
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
10.1073/pnas.1002713107 · 2010 · External reference
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
10.1038/bjc.2013.74 · 2013 · External reference
Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53
10.1158/1078-0432.ccr-21-0715 · 2021 · External reference
Unresolved reference
External reference
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
10.1073/pnas.0908201106 · 2009 · External reference
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
10.1126/science.1183057 · 2010 · External reference
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: A first-in-human, open-label, multicentre, phase 1 study
10.1016/s2468-1253(22)00167-4 · 2022 · External reference
260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free survival (PFS) results
10.1016/j.annonc.2025.05.275 · 2025 · External reference
On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site
10.3762/bjoc.14.80 · 2018 · External reference
Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors
10.1056/nejmoa1607427 · 2017 · External reference
Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes
1991 · External reference
Increased exposure of anionic phospholipids on the surface of tumor blood vessels
2002 · External reference
Cationic amphiphilic peptides with cancer-selective toxicity
10.1016/j.ejphar.2009.08.043 · 2009 · External reference
Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment
10.1517/13543784.15.8.933 · 2006 · External reference
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide
10.1158/0008-5472.can-05-4569 · 2006 · External reference
The future of peptide-based drugs
10.1111/cbdd.12055 · 2013 · External reference
Strategies to improve plasma half life time of peptide and protein drugs
10.1007/s00726-005-0289-3 · 2006 · External reference
A biomimetic approach for enhancing the in vivo half-life of peptides
10.1038/nchembio.1907 · 2015 · External reference
Cyclic peptide therapeutics: Past, present and future
10.1016/j.cbpa.2017.02.006 · 2017 · External reference
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
10.1038/nchembio.184 · 2009 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The entry of nanoparticles into solid tumours
10.1038/s41563-019-0566-2 · 2020 · External reference
Synthesis of proteins by automated flow chemistry
10.1126/science.abb2491 · 2020 · External reference
Sustainability challenges in peptide synthesis and purification: From R&D to production
10.1021/acs.joc.8b03001 · 2019 · External reference
Unresolved reference
External reference
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(14)70379-1 · 2014 · External reference
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development
10.1021/acs.jmedchem.3c00623 · 2023 · External reference
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists
10.1021/jm970832g · 1999 · External reference
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate
10.1007/s00259-002-1050-8 · 2003 · External reference
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
10.1126/science.aao2774 · 2018 · External reference
Organoid modeling of the tumor immune microenvironment
10.1016/j.cell.2018.11.021 · 2018 · External reference
Unresolved reference
External reference
Design of target specific peptide inhibitors using generative deep learning and molecular dynamics simulations
10.1038/s41467-024-45766-2 · 2024 · External reference
Target sequence-conditioned design of peptide binders using masked language modeling
10.1038/s41587-025-02761-2 · 2026 · External reference
Cyclic peptide structure prediction and design using AlphaFold2
10.1038/s41467-025-59940-7 · 2025 · External reference
ACPred-FL: A sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides
10.1093/bioinformatics/bty451 · 2018 · External reference
AntiCP 2.0: An updated model for predicting anticancer peptides
10.1093/bib/bbaa153 · 2021 · External reference
Benchmarks in antimicrobial peptide prediction are biased due to the selection of negative data
10.1093/bib/bbac343 · 2022 · External reference
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate
10.1007/s00259-002-1050-8 · ExternalCitation · doi-reference
Strategies to improve plasma half life time of peptide and protein drugs
10.1007/s00726-005-0289-3 · ExternalCitation · doi-reference
260MO AGITG ASCEND study: Randomised, double-blind phase II study of certepetide (CERT) or placebo (PLA) added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC): Cohort B progression-free survival (PFS) results
10.1016/j.annonc.2025.05.275 · ExternalCitation · doi-reference
Therapeutic peptides: Historical perspectives, current development trends, and future directions
10.1016/j.bmc.2017.06.052 · ExternalCitation · doi-reference
Cyclic peptide therapeutics: Past, present and future
10.1016/j.cbpa.2017.02.006 · ExternalCitation · doi-reference
Organoid modeling of the tumor immune microenvironment
10.1016/j.cell.2018.11.021 · ExternalCitation · doi-reference
Cationic amphiphilic peptides with cancer-selective toxicity
10.1016/j.ejphar.2009.08.043 · ExternalCitation · doi-reference
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(14)70379-1 · ExternalCitation · doi-reference
Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: A first-in-human, open-label, multicentre, phase 1 study
10.1016/s2468-1253(22)00167-4 · ExternalCitation · doi-reference
Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development
10.1021/acs.jmedchem.3c00623 · ExternalCitation · doi-reference
Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptide
10.1021/acs.jmedchem.5b02025 · ExternalCitation · doi-reference
Sustainability challenges in peptide synthesis and purification: From R&D to production
10.1021/acs.joc.8b03001 · ExternalCitation · doi-reference
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists
10.1021/jm970832g · ExternalCitation · doi-reference
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours
10.1038/bjc.2013.74 · ExternalCitation · doi-reference
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
10.1038/nchembio.184 · ExternalCitation · doi-reference
A biomimetic approach for enhancing the in vivo half-life of peptides
10.1038/nchembio.1907 · ExternalCitation · doi-reference
Design of target specific peptide inhibitors using generative deep learning and molecular dynamics simulations
10.1038/s41467-024-45766-2 · ExternalCitation · doi-reference
Cyclic peptide structure prediction and design using AlphaFold2
10.1038/s41467-025-59940-7 · ExternalCitation · doi-reference
The entry of nanoparticles into solid tumours
10.1038/s41563-019-0566-2 · ExternalCitation · doi-reference
Trends in peptide drug discovery
10.1038/s41573-020-00135-8 · ExternalCitation · doi-reference
Target sequence-conditioned design of peptide binders using masked language modeling
10.1038/s41587-025-02761-2 · ExternalCitation · doi-reference
Cytotoxic and antitumor peptides as novel chemotherapeutics
10.1039/d0np00019a · ExternalCitation · doi-reference
Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors
10.1056/nejmoa1607427 · ExternalCitation · doi-reference
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
10.1073/pnas.0908201106 · ExternalCitation · doi-reference
Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic
10.1073/pnas.1002713107 · ExternalCitation · doi-reference
AntiCP 2.0: An updated model for predicting anticancer peptides
10.1093/bib/bbaa153 · ExternalCitation · doi-reference
Benchmarks in antimicrobial peptide prediction are biased due to the selection of negative data
10.1093/bib/bbac343 · ExternalCitation · doi-reference
ACPred-FL: A sequence-based predictor using effective feature representation to improve the prediction of anti-cancer peptides
10.1093/bioinformatics/bty451 · ExternalCitation · doi-reference
Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification
10.1098/rsob.200004 · ExternalCitation · doi-reference
The future of peptide-based drugs
10.1111/cbdd.12055 · ExternalCitation · doi-reference
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix
10.1126/science.1099191 · ExternalCitation · doi-reference
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
10.1126/science.1183057 · ExternalCitation · doi-reference
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
10.1126/science.aao2774 · ExternalCitation · doi-reference
Synthesis of proteins by automated flow chemistry
10.1126/science.abb2491 · ExternalCitation · doi-reference
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide
10.1158/0008-5472.can-05-4569 · ExternalCitation · doi-reference
Safety, antitumor activity, and T-cell responses in a dose-ranging phase I trial of the oncolytic peptide LTX-315 in patients with solid tumors
10.1158/1078-0432.ccr-20-3435 · ExternalCitation · doi-reference
Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53
10.1158/1078-0432.ccr-21-0715 · ExternalCitation · doi-reference
Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment
10.1517/13543784.15.8.933 · ExternalCitation · doi-reference
Antimicrobial peptides with selective antitumor mechanisms: Prospect for anticancer applications
10.18632/oncotarget.16743 · ExternalCitation · doi-reference
On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site
10.3762/bjoc.14.80 · ExternalCitation · doi-reference
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application
10.3892/ijo.2020.5099 · ExternalCitation · doi-reference
